Crystal Pharmatech Co., Ltd.

Crystal Pharmaceutical (suzhou) Co., Ltd.

Merck Sharp + Dohme Corp.

Receptos, Inc.

Suzhou Pengxu Pharmatech Co., Ltd.

Agios Pharmaceuticals, Inc.

Glaxosmithkline Intellectual Property (no.2) Limited

Anacor Pharmaceuticals, Inc.

Napp Pharmaceutical Group Limited

Crystal Pharmatech Inc.

Crystal Pharmaceuticals (suzhou) Co., Ltd.

Wuhan Kaidi Engineering Technology Research Institute Co., Ltd.

Zhongying Changjiang International New Energy Investment Co., Ltd.

Glaxosmithkline Intellectual Property Limited

Crystal Pharmaceutical Co., Ltd.

Yanfeng Zhang

Minhua Chen

Xiaoyu Zhang

Chaohui Yang

Xiaoting Zhai

Kaiqiang Yan

Kai Liu

Nan Xia

Xiaojuan Diao

Po Zou

Yilong Chen

Fei Lu

Jiaoyang Li

Jinqiu Wang

Peng Wang

Pixu Li

Chunxiang Huang

Jianming Wang

Liang Zhang

John Y L Chung

Chong-Hui Gu

Samuel V Agresta

Jeremy Peter Scott

Aaron S Cote

Wenyan Liu

David Schenkein

Hua Yang

Liting Guo

Qiyue Liu

Yekaterina Vaynshteyn

Zhen Tang

Yan Zhou

Tesfaye Biftu

Ping Chen

Laura Marie Artino

Faye Sheen

Aaron J Moment

Itzia Arroyo

Donal Desmond

Davida Krueger

Yuhao Chen

Robert Michael Hughes

Xingcai Zheng

Leiming Tao

Martin Patrick Hughes

Zhangjian Fang

Ian Mangion

Qingping Yang

Hongming Tang

Shu Yu

Alfred Lee

Yuan Liu

Yannick Borguet

Benjamin D Sherry

Michael J McNevin

Jiale Qian

Hui Gao

Yong Liu

Yuting Cheng

Joyce Stellabott

Kung-I Feng

Zhijiu Zhuo

Gary Martin

Jianwei Shen

Cen Chen

Alan Thompson

Tracy Walker

Jennifer Baxter

Heng Ge

Shulin Ji

Ryan Cohen

Scott Schultz

Cunbo Yang

Lie Chen

The present invention relates to crystalline polymorphs of an echinocandin antifungal agent and novel methods for their preparation.

Polymorph of echinocandin antifungal agent

The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Crystalline forms of ozanimod and processes for preparation thereof

The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

Crystal forms of crisaborole in free form and preparation method and use thereof

The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development. 

Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof. 

Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof

A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.

Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof

The present disclosure relates to a crystalline form of compound I and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing serotonin, norepinephrine and dopamine triple reuptake inhibitors drugs, and/or use of the crystalline form for preparing drugs treating nervous system disorders. The crystalline form of the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development. 

Crystalline form of EB-1020, processes for preparation and use thereof

The present disclosure relates to novel crystalline forms of compound (I) and processes for preparation and use thereof. Crystalline forms CS3, CS2, CS5 and CS8 of compound (I) of the present disclosure have advantages in at least one aspect of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification effect, flowability, adhesiveness, stability in drug product, in vitro and in vivo dissolution, etc., which provides new and better choices for preparation of drug product containing compound (I) and has significant values for future drug development. 

Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof

The present disclosure relates to crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art and have significant values for future drug optimization and development. 

Crystal form of Baricitinib and preparation method thereof

The present disclosure is related to crystalline forms of ozanimod hydrochloride, as well as preparation method thereof. The crystalline form of ozanimod hydrochloride provided by the present disclosure can be used for treating autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The crystalline form of the present disclosure has advantages in at least one aspect of solubility, melting point, stability, dissolution, bioavailability and processability and provides a new and better choice for the preparation of drug product containing ozanimod, and has significant value for drug development. 

Crystalline form of ozanimod hydrochloride, and processes for preparation thereof

The present disclosure relates to novel crystalline forms of acalabrutinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing acalabrutinib, use of acalabrutinib for preparing Bruton's tyrosine kinase inhibitor drug, and use of acalabrutinib for preparing drugs treating mantle cell lymphoma. The crystalline forms of the present disclosure have one or more improved properties compared with prior art, and have significant value for future drug optimization and development. 

Crystal form of acalabrutinib and preparation method and use thereof

The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs. 

Crystalline forms of ARN-509, preparation method and use thereof

Growing community of inventors

Suzhou, China

Yanfeng Zhang